Saroglitazar Magnesium 1 mg ( DrugBank: Saroglitazar, Magnesium )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 93 | 原発性胆汁性胆管炎 | 1 |
93. 原発性胆汁性胆管炎
臨床試験数 : 282 / 薬物数 : 245 - (DrugBank : 56) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 113
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05133336 (ClinicalTrials.gov) | March 15, 2022 | 1/11/2021 | Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis | A Multicenter, Randomized, Double-blind, Placebo Controlled, Phase 2b/3 Study to Evaluate the Efficacy and Safety of Saroglitazar Magnesium in Subjects With Primary Biliary Cholangitis | Primary Biliary Cholangitis | Drug: Saroglitazar Magnesium 1 mg;Drug: Saroglitazar Magnesium 2 mg;Drug: Placebo | Zydus Therapeutics Inc. | NULL | Not yet recruiting | 18 Years | 75 Years | All | 192 | Phase 2/Phase 3 | NULL |